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Metabolic syndrome is a serious health condition that affects approximately 34% of adults. 
Hallmarks of this syndrome include abdominal obesity, elevated triglycerides, reduced high-
density lipoprotein (HDL) cholesterol levels, hypertension, hyperglycemia, and insulin 
resistance, and those affected are at heightened risk for the development of type 2 diabetes, 
cardiovascular disease, and stroke. Over the past 20 years, an increasing role for low grade, 
sterile inflammation in insulin resistance and metabolic syndrome has been appreciated. 
Studies have shown that obesity induces an inflammatory state that is clinically manifested 
as altered concentrations of acute-phase response proteins (eg, increased C-reactive protein), 
proinflammatory cytokines (eg, increased interleukin [IL]-6 and tumor necrosis factor 
[TNF]α), adipokines (eg, reduced adiponectin and elevated resistin and leptin), coagulation 
factors (eg, increased plasminogen activator inhibitor-1), and increased white blood cell 
counts in the circulation. Data from rodent models and clinical samples support the idea that 
the vast majority of these proinflammatory mediators primarily originate from expanding 
adipose tissue depots. A variety of leukocytes (eg, macrophages, monocytes, dendritic cells, 
eosinophils, neutrophils, T cells, B cells, and natural killer T [NKT] cells) are now known to 
reside in adipose tissue, and these cells are either activated or recruited to fat in response to 
obesity. Infiltrating immune cells, and the proinflammatory cytokines/chemokines they 
produce, interact with metabolically stressed cells to generate a proinflammatory milieu that 
exacerbates insulin resistance not only in fat but in multiple metabolic tissues to promote 
metabolic syndrome.
Adipose tissue macrophages (ATMs) are the most abundant immune cell population in fat 
and were the first tissue leukocyte population linked to obesity-induced metabolic disease 
and inflammation in both mouse models and humans.1,2 Tissue macrophages adapt a range 
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of functional activation states, with “classically activated,” proinflammatory M1 
macrophages and “alternatively activated,” anti-inflammatory M2 macrophages representing 
extreme ends of a continuum.3 In lean mice and humans, ATMs in visceral fat are “M2-
like,” reside between adipocytes, produce anti-inflammatory cytokines (eg, IL-10), and 
contribute to tissue homeostasis.4–6 In response to obesity, a second phenotypically and 
functionally distinct population of macrophages accumulates in fat. These ATMs express 
markers of proinflammatory M1 macrophages and produce proinflammatory cytokines (eg, 
TNFα, IL-1β, and IL-6) known to impair insulin sensitivity in adipose tissue.4,7–12 In mice, 
“M1-like” ATMs are recruited in response to lipolysis13 and aggregate around dead and 
hypoxic adipocytes,14,15 suggesting that metabolic stress is a primary driving force for 
macrophage recruitment in adipose tissue. Collectively, these and other findings led to the 
“phenotypic switch” model, which proposes that obesity induces a collective shift in the 
activation state of ATMs from an anti-inflammatory “M2-like” state that protects adipocytes 
to a proinflammatory “M1-like” state that contributes to insulin resistance.4 More recently, 
this linear paradigm has been challenged by proteomic studies demonstrating that human 
macrophages in fat have a “metabolically activated” phenotype that differs from classical 
M1 polarization.16 Nonetheless, it is clear that macrophages accumulate in fat depots with 
obesity, and these cells can alter the inflammatory milieu to promote local and systemic 
dysfunction.
Even as being overweight (body mass index [BMI] = 25–29.9 kg/m2) and obese (BMI ≥ 30 
kg/m2) is strongly associated with the likelihood of developing adipose tissue inflammation 
and insulin resistance, a fraction of obese people never fully manifest metabolic syndrome, 
insulin resistance, or diabetes.17,18 These “metabolically healthy (MH) obese” individuals 
provide unique insight into pathogenesis of metabolic disease. Paradoxically, epidemiologic 
studies indicate that a subset of individuals with “normal” body weight (BMI <24.9 kg/m2) 
may also develop insulin resistance and metabolic syndrome during their lifetime. Although 
the latter are more rarely studied, “metabolically unhealthy (MU) lean” subjects may hold 
equally important new clues into the origins of metabolic syndrome and its sequela.
In this issue of Translational Research, Moreno-Indias et al. have attempted to address this 
knowledge gap. The authors investigated the expression levels of human macrophage 
markers, including CD68, CD33, CD11c, CD163, MerTK, CD64, and CD206, in visceral 
and subcutaneous adipose tissue (SAT) depots in normal-weight (BMI <24.9 kg/m2) subjects 
stratified into MH or MU populations, based on indices of metabolic syndrome.19 Despite 
having comparable BMI, the MU group had significantly elevated fasting glucose, higher 
triglyceride levels, increased total and low-density lipoprotein (LDL) cholesterol levels, and 
lower HDL cholesterol levels than the MH group. As predicted, MU subjects had more 
relative insulin resistance, as indicated by increased HOMA-IR levels, as well as elevated 
serum insulin and c-peptide levels.
Despite marked differences in metabolic indices between MH and MU, there were no 
differences in the expression of macrophage markers in visceral adipose tissue between the 
two groups. This was surprising given the relationship between visceral/omental fat 
inflammation, ATM content, and insulin resistance/metabolic syndrome previously 
documented in obese adults. Furthermore, although serum C-reactive protein levels were 
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higher in MU subjects, the expression of proinflammatory cytokines (IL-1β, IL-6, and 
TNFα) and chemokines associated with leukocyte recruitment (CCL2 and CCL3) was not 
different between groups, irrespective of the adipose tissue depot surveyed. Rather, CD68, 
CD11c, CD163, CD33, MerTK, and CD206 messenger RNA levels were unexpectedly 
elevated in SAT from MU subjects. Notably, peroxisome proliferator-activated receptor 
gamma (PPARγ) expression was also lower in SAT from MU subjects, suggesting a 
relationship between adipose tissue dysfunction and macrophage infiltration in the 
subcutaneous depot.
These findings fall in line with other reports. For instance, Wentworth et al.11 reported that 
CD11c 1 CD2061 ATMs accumulate in visceral as well as subcutaneous depots collected 
from obese women. Notably, the number of CD11c + CD206+ ATMs was even greater in 
obese subjects with metabolic syndrome. In a more recent study, the expression of CD163 in 
subcutaneous fat was previously shown to positively correlate with HOMA-IR in obese 
patients.20 Although CD11c + CD206+ or CD163+ ATMs were not enumerated in the 
present study, the transcriptional profile (elevated macrophage markers with reduced PPARγ 
expression) supports a model in which ATMs accumulate in SAT to potentially promote 
insulin resistance and metabolic dysfunction in that depot. What sets the work of Moreno-
Indias et al. apart is the documentation of these phenomena in normal-weight subjects with 
indices of metabolic syndrome, suggesting an important but largely unexplored link between 
ATMs and metabolic syndrome that arises independent of obesity and inflammation in 
visceral fat.
At the same time, the Moreno-Indias study reminds us of the “chicken-and-egg” question 
that continues to remain largely unanswered—Does recruitment of ATMs to fat depots cause 
insulin resistance and metabolic dysfunction, or does insulin resistance/metabolic 
dysfunction precipitate recruitment of ATMs to fat? Studies in mice models of obesity (both 
genetic and diet induced) largely favor the hypothesis that accumulating, proinflammatory 
ATMs promote chronic tissue inflammation and exaggerate insulin resistance.1,2,4,21 
Certainly, ablating macrophages in obese mice or preventing macrophage recruitment into 
adipose tissue improves glucose tolerance, insulin sensitivity, and metabolic function.22–24 
However, there are also studies that suggest metabolic dysfunction precedes ATM 
recruitment and activation. For example, induced lipolysis13 and adipocyte apoptosis25 result 
in massive infiltration of ATMs to visceral fat in the mouse. More recently, the Czech 
laboratory demonstrated that circulating cytokine profiles more closely associate with serum 
insulin levels rather than BMI in human subjects and that pharmacologically correcting 
hyperinsulinemia and hyperglycemia in obese mice limits ATM accumulation and adipose 
tissue inflammation.26 The effects in mice may be explained, at least in part, by direct 
effects of obesity, hyperglycemia, hyperinsulinemia, or a combination thereof on the process 
of myelopoiesis,27–29 which would give rise to pools of monocytes capable of infiltrating 
adipose tissue, ultimately giving rise to proinflammatory ATMs. Notably, one recent human 
study reported that monocyte and lymphocyte markers are increased in subcutaneous fat of 
obese women following 3-hour-long hyperglycemic clamps.30 Although Tencerova et al. did 
not assess ATM content, their work suggests that hyperglycemia may provoke a coordinated 
immune response in adipose tissue.
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Study limitations make it difficult to establish a clear causal relationship between adipose 
tissue leukocyte content, inflammation, and indices of metabolic syndrome in human 
subjects. In the future, the Precision Medicine Initiative could be leveraged to support 
studies aimed at assessing the contribution of various adipose tissue leukocytes to tissue 
inflammation longitudinally in metabolically defined populations. Given the sheer volume of 
bariatric procedures performed in this country annually, and the high retention rates in the 
National Institutes of Health Longitudinal Assessment of Bariatric Surgery consortium,31 it 
seems reasonable that prospective, multi-site studies can address the relationship between 
surgery-induced weight loss, changes in adipose tissue immune cell composition, and insulin 
sensitivity over time. By contrast, determining whether leukocyte infiltration and 
proinflammatory activation leads to metabolic disease in humans will be a much more 
challenging endeavor, as this pathophysiology could take decades to develop. Nonetheless, 
the findings by Moreno-Indias et al. suggest that studying an often overlooked population—
the MU lean—may also lead to advances. Clearly new prospective studies should include as 
many metabolic parameters from as many divergent phenotypic populations as possible, as it 
is becoming increasingly clear that BMI alone is not strongly correlated with adipose tissue 
leukocytosis, metabolic syndrome, and disease risk.
To be successful, new research initiatives also have to address another recurring limitation of 
human studies: getting the most information from a small bio-specimen. Most laboratories 
have the capacity to perform gene expression profiling or cytokine measurements from fat 
biopsies. Although this gives a general sense as to the relative state of inflammation or 
leukocyte infiltration within the fat depots, this approach fails to take into consideration the 
cellular complexity of adipose tissue and the wide heterogeneity of adipose tissue 
leukocytes. For example, CD206 is expressed by at least 2 distinct populations of 
macrophages in human fat11,20,32; therefore, CD206 messenger RNA levels can only serve 
as a surrogate for macrophage accumulation and cannot be used to infer which macrophage 
subset is amassing. To overcome this limitation, tissue dissociation and flow cytometry 
techniques have been developed that allow for not only the enumeration and 
immunophenotyping of adipose tissue stromal cells but also isolation of these cells for gene 
expression profiling and functional studies.33–35 Nonetheless, our collective understanding 
of the immune cell repertoire in human adipose tissue depots is still in its infancy. Emerging 
“-omics” techniques, including single-cell RNA-seq and mass cytometry (eg, CyTOF), have 
the capacity to deeply interrogate the transcriptome and proteome (and underlying systems 
biology) of rare tissue leukocytes with single cell resolution.36–38 Adopting these platforms, 
developing suitable workflows for limited adipose tissue samples (eg, needle biopsies) from 
a variety of depots, and implementing unbiased computational analysis of the resulting data 
sets promises to greatly accelerate our basic understanding of human adipose tissue 
leukocyte diversity in lean and obese subjects.
Given the prevalence of obesity and metabolic syndrome, understanding the underlying 
biology of human adipose tissue inflammation and its relationship with cardiovascular 
disease, type 2 diabetes, and stroke is a question of paramount importance. Specifically, 
findings presented by Moreno-Indias et al. in this issue suggest that adipose tissue 
leukocytes may also be key determinants of metabolic fitness even in normal-weight 
subjects. Clearly, their results suggest there is more to glean from studying the lean.
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